347 Participants Needed

ICCAN Program for Cancer

Recruiting at 12 trial locations
JL
Francesca Gany, MD, MPH profile photo
Overseen ByFrancesca Gany, MD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine how effectively the Integrated Cancer Care Access Network (ICCAN) program helps patients complete their cancer treatment and improves their quality of life. It compares the ICCAN program to regular hospital services, such as meetings with a Social Worker or Patient Navigator, in New York City hospitals. The trial targets cancer patients currently receiving or about to start chemotherapy or radiation therapy. Eligible participants should be fluent in English, Spanish, or Mandarin and plan to remain in the area for at least one year.

As an unphased trial, this study provides a unique opportunity to contribute to innovative cancer care solutions that could enhance treatment experiences for future patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the ICCAN program is safe?

Research has shown that the Integrated Cancer Care Access Network (ICCAN) positively impacts patients' treatment experiences. One study found that patients in the ICCAN program were more likely to complete their treatment and reported better outcomes than those receiving standard care. This suggests that patients generally respond well to the program.

Although specific safety data for ICCAN is limited, the absence of reported negative effects is reassuring. ICCAN provides guidance and resources, making it a low-risk option. This non-invasive support helps patients manage their treatment and access necessary resources.

Overall, evidence suggests that ICCAN is a safe and effective way to enhance cancer treatment experiences.12345

Why are researchers excited about this trial?

Researchers are excited about the Integrated Cancer Care Access Network (ICCAN) trial because it aims to improve cancer treatment completion and quality of life, especially for underserved groups like Black, Hispanic, and low socioeconomic status patients with triple-negative breast cancer. Unlike standard treatments that primarily focus on medical care, ICCAN integrates social and economic support resources, potentially addressing key barriers to treatment adherence. By refining and testing this comprehensive support network, the trial hopes to reveal new ways to enhance the overall cancer care experience, potentially leading to better outcomes and improved quality of life for patients who might otherwise face significant challenges.

What evidence suggests that the ICCAN program is effective for cancer care?

Research has shown that the Integrated Cancer Care Access Network (ICCAN), which participants in this trial may receive, helps more patients complete their cancer treatments. Studies have found that patients in the ICCAN program experience better health and a higher quality of life compared to those receiving standard care. This program is particularly helpful for patients from low-income backgrounds, as it improves their access to necessary resources. The data indicates that ICCAN significantly aids patients in managing their cancer treatment effectively. Overall, evidence supports that ICCAN can improve treatment completion and enhance patient well-being.12467

Who Is on the Research Team?

FG

Francesca Gany, MD, MS

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

You are intent on staying in the vicinity for a minimum of twelve months.
Is the treating physician administering care to a participant enrolled in the study?
You are a participant in the study.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either the ICCAN program or standard hospital services for cancer treatment

12 months

Follow-up

Participants are monitored for treatment completion and quality of life outcomes

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • The Integrated Cancer Care Access Network (ICCAN)
  • Usual and Customary Group (U&C)

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Phase II, Arm 2: ICCAN-IOExperimental Treatment1 Intervention
Group II: Phase II, Arm 1: Usual and Customary Care (U&C)Experimental Treatment1 Intervention
Group III: Phase I: RefinementExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Ralph Lauren Center for Cancer Care and Prevention

Collaborator

Trials
8
Recruited
2,200+

The City College of New York

Collaborator

Trials
32
Recruited
6,700+

Lincoln Medical and Mental Health Center

Collaborator

Trials
11
Recruited
2,100+

Lutheran Medical Center

Collaborator

Trials
1
Recruited
350+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Citations

Integrated Cancer Care Access Network

Data collected from ICCAN patients will help us to increase the number of patients who complete their cancer treatment, improve the quality of life for low- ...

Memorial Sloan Kettering

MSK is collecting data across four key levels to evaluate its access facilitators and the effectiveness of the ICCAN Network including metrics at the patient, ...

Impact of ICCAN on Cancer Treatment Completion and ...

The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in ...

Improving adherence to cancer care for socioeconomically ...

While ICCAN has been shown to increase treatment adherence and completion for patients with other cancers, it has not historically enrolled patients with CNS ...

5.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40494401/

A Randomized Controlled Trial of the Integrated Cancer ...

Conclusions: Patients in the ICCAN arm had significantly better treatment completion and patient-reported outcomes than those receiving U&C.

Study Details | NCT01742143 | Impact of ICCAN on Cancer ...

The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in ...

A Randomized Controlled Trial of the Integrated Cancer ...

Conclusions: Patients in the ICCAN arm had significantly better treatment completion and patient-reported outcomes than those receiving U&C.